Revenue (EUR million)
Press Release
Copenhagen
In 2024, the Abacus Medicine Group celebrated 20 years of strong, organic growth. Revenue grew 23% to EUR 1,487 million, while EBITDA reached a record high of EUR 50.5 million and the Free cash flow was EUR 26.4 million.
The revenue growth for the group was based on a combination of increased sales in both new and existing markets, and entering into long-term partnerships. The Pharma Wholesale division continued last year’s extraordinary performance and achieved 35% revenue growth.
“Our financial robustness gives us a lot of strategic opportunities. In 2024, this allowed us to accelerate investments in our ambitious Access26 strategy, with a particular focus on people and digital excellence. We are already seeing the impact, exemplified by the impressive growth of our wholesale business,” says CEO Flemming Wagner.
Financial robustness leaves room for accelerated investments
While the Group invested heavily in 2024, a strong operational performance and net working capital management lead to a record free cash flow generation of EUR 26.4 million.
The Abacus Medicine Group expects to build further on the good momentum in 2025 with an Outlook of revenue growth of 14-18% and an EBITDA margin of 3.3-3.7%. The Group will continue to invest strategically in operational capacity, digital excellence, and people to deliver profitable growth.
View the full Annual Report 2024 for the Abacus Medicine Group
Contact
Flemming Wagner, CEO
Mobile: +45 20 40 80 21, fw@abacusmedicine.com
Kasper Lytthans, Head of Investor Relations and M&A
Mobile: +45 30 80 89 16, kasper.lytthans@abacusmedicine.com
Ole Lindhardt, Head of Global Communications and Marketing
Mobile: +45 20 18 39 52, ole.lindhardt@abacusmedicine.com
About the Abacus Medicine Group
The activities of the Abacus Medicine Group are organised in three divisions: Pharma Trading, Pharma Services and Pharma Wholesale. The main brands of each division are:
- Abacus Medicine – among the leaders in the European market for parallel distribution of medicine
- Abacus Medicine Pharma Services – supports pharmaceutical companies with the commercialisation of new therapies
- Pluripharm – operates as a wholesaler and supplies medicine, medical devices, and related services to pharmacies, hospitals and directly to thousands of patients in the Netherlands.
The group numbered 1,505 employees at year-end 2024.